NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated August 1, 2026

Supplement × Prescription·Evidence index

Potassium and Valsartan: what the published research says

PubMed indexes 4 records that name Potassium and Valsartan together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.

Read this first

An evidence index, not guidance.

Every statement below is attributed to a named, dated, linked source.

This page lists published research relevant to Potassium and Valsartan. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.

The research

4 studies naming Potassium and Valsartan.

Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.

Comparative analysis of sacubitril/valsartan and losartan potassium in the treatment of hypertension: efficacy, adverse reactions, and observations.

American journal of translational research · 2023 · PMID 37854234

166 participants

“For patients with hypertension, sacubitril/valsartan has a better treatment efficacy than losartan potassium, because it can effectively reduce blood pressure, the levels of inflammatory factors, and the rate of adverse reactions in patients.”

Ye et al. · Authors' conclusion

Names both Potassium and Valsartan in its title.

Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.

European journal of heart failure · 2021 · PMID 33609066

Randomized Controlled Trial

“Both hypo- and hyperkalaemia were associated with heart failure hospitalisation but only hypokalaemia was associated with mortality, especially in the context of renal impairment. Hypokalaemia was as strongly associated with death from non-cardiovascular causes as with cardiovascular death. Collectively, these findings suggest that potassium disturbances are a more of a marker of HFpEF severity rather than a direct cause of death.”

Ferreira et al. · Authors' conclusion

Names Potassium and Valsartan together in an interaction, co-administration, or pharmacokinetic context.

ACE inhibitors in heart failure: what more do we need to know?

American journal of cardiovascular drugs : drugs, devices, and other interventions · 2005 · PMID 16259523

Comparative StudyReviewHuman subjects

Names Potassium and Valsartan together in an interaction, co-administration, or pharmacokinetic context.

Limitations

What this evidence cannot tell you.

Search-based evidence indexes have real limits, and it is worth being explicit about them:

NutriStack

Track what you actually take.

NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Potassium, Valsartan, and several hundred other substances.

The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.